Artemis Therapeutics (ATMS) Stock Price, News & Analysis

Company Overview

Artemis Therapeutics, Inc. is a biopharmaceutical company. It develops new treatments for serious and life-threatening infections. It Includes cytomegalovirus and malaria. The company was founded on April 22, 1997 and was headquartered in New York, NY.

Key Stats

• Today's Range: $0.0021 to $0.0021
• 50-Day Range: N/A
• 52-Week Range: $0.11 to $5.00
• Volume: N/A
• Average Volume: 2,942 shs
• Market Capitalization: $235,271.40
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ATMS Stock Analysis - Frequently Asked Questions

How have ATMS shares performed this year?

Artemis Therapeutics' stock was trading at $0.0021 at the start of the year. Since then, ATMS stock has increased by 0.0% and is now trading at $0.0021.
View the best growth stocks for 2025 here.

How do I buy shares of Artemis Therapeutics?

Shares of ATMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Artemis Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Artemis Therapeutics investors own include SiteOne Landscape Supply (SITE), Nabriva Therapeutics (NBRV), Meta Platforms (META), Gemini Therapeutics (GMTX), ERYTECH Pharma (ERYP) and Bruush Oral Care (BRSH).

Company Calendar

• Today: 1/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Miscellaneous chemical products
• Sub-Industry: Consumer Goods
• Current Symbol: OTCMKTS:ATMS
• CUSIP: N/A
• CIK: 1062128
• Web: www.artemis-therapeutics.com
• Phone: (646) 233-1454
• Fax: 800-253-5177
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-1,360,000.00
• Net Margins: -299.54%
• Pretax Margin: -299.54%
• Return on Equity: N/A
• Return on Assets: -425.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.15
• Quick Ratio: 0.12

Sales & Book Value

• Annual Sales: $310,000.00
• Price / Sales: 0.76
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.01) per share
• Price / Book: -0.21

Miscellaneous

• Outstanding Shares: 112,034,000
• Free Float: 103,687,000
• Market Cap: $235,271.40
• Optionable: Not Optionable
• Beta: -1.92